丁基-噻唑-2-基-胺 | 69212-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 丁基-噻唑-2-基-胺
• 英文名称: butyl-thiazol-2-yl-amine
• 英文别名: N-butyl-1,3-thiazol-2-amine
• CAS: 69212-65-3
• 化学式: C₇H₁₂N₂S
• mdl: MFCD06408499
• 分子量: 156.252
• InChiKey: BAJHQTXOZZKKCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丁基-噻唑-2-基-胺 以 1,4-二氧六环 、 甲苯 为溶剂， 生成 N-Butyl-N-[5-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-thiazol-2-yl]-benzamide
  参考文献：
  名称：

  Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors

  摘要：

  A series of heteroaryl-substituted bis-trifluoromethyl carbinols were prepared and evaluated as malonyl-CoA decarboxylase (MCD) inhibitors. Some thiazole-based derivatives showed potent in vitro MCD inhibitory activities and significantly increased glucose oxidation rates in isolated working rat hearts. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.100
• 作为产物：
  描述：

  N-(thiazol-2-yl)butyramide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 丁基-噻唑-2-基-胺
  参考文献：
  名称：

  中性黄嘌呤类似物作为环状AMP磷酸二酯酶的抑制剂。

  摘要：

  合成了两种中离子黄嘌呤类似物的几种衍生物，即中离子噻唑并[3,2-α嘧啶-5,7-二酮]和1,3,4-噻二唑并[3,2-α嘧啶-5,7-二酮]。并被评估为环状AMP磷酸二酯酶的抑制剂。这些化合物中大量显示出茶碱样活性。

  DOI：

  10.1002/jps.2600671236

文献信息

• SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS
  申请人：Gaul Michael

  公开号：US20080286265A1

  公开（公告）日：2008-11-20

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

  本发明涉及化合物的公式（I），制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童关节炎，银屑病性关节炎，反应性关节炎），与骨相关的疾病（包括与骨形成有关的疾病），乳腺癌（包括对抗雌激素治疗无效的癌症），心血管疾病，软骨相关疾病（如软骨损伤/丧失，软骨退化，以及与软骨形成有关的疾病），软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态紊乱，痛风，假性痛风，脂质紊乱，代谢综合征，多发性骨髓瘤，肥胖，骨关节炎，成骨不全症，骨溶解性骨转移，软骨软化症，骨质疏松症，Paget病，牙周病，多肌痛风，Reiter综合征，重复性应激损伤，高血糖，血糖水平升高和胰岛素抵抗等病症的条件。
• Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
  申请人：——

  公开号：US20040082576A1

  公开（公告）日：2004-04-29

  The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

  本发明涉及新颖化合物（I）、它们的前药以及药学上可接受的盐，以及含有这种化合物的制药组合物，用于治疗某些代谢疾病和受酰辅酶A丙酮酸羧化酶（丙酮酸辅酶A羧化酶，MCD）抑制调节的疾病。具体而言，本发明涉及化合物和组合物以及通过抑制受酰辅酶A丙酮酸羧化酶的方法预防、管理和治疗心血管疾病、糖尿病、酸中毒、癌症和肥胖症。
• Malonyl-CoA Decarboxylase Inhibitors Useful as Metabolic Modulators
  申请人：Arrhenius Thomas

  公开号：US20100016259A1

  公开（公告）日：2010-01-21

  The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

  本发明涉及新型化合物(I)及其前药，以及药学上可接受的盐和含有这种化合物的制剂。这些化合物在治疗某些代谢性疾病和受酰辅酶A丙酮酸羧化酶(malonyl-CoA decarboxylase，MCD)抑制调节的疾病方面有用。具体而言，本发明涉及化合物和制剂以及通过抑制受酰辅酶A丙酮酸羧化酶的预防、管理和治疗心血管疾病、糖尿病、酸中毒、癌症和肥胖症的方法。
• 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
  申请人：Ennis Michael Dalton

  公开号：US20080176857A1

  公开（公告）日：2008-07-24

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药物可接受的盐，其中化合物具有公式I的结构：其中A1、A2、A3、A4、A5、A6、A7、A8、X4、X6、R2、R4、R5和R6如本发明详细描述中所定义。本发明还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US07524969B2

  公开（公告）日：2009-04-28

  The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to compounds and compositions and the methods for the prophylaxis, management and treatment of cardiovascular diseases, diabetes, acidosis, cancers, and obesity through the inhibition of malonyl-coenzyme A decarboxylase.

  本发明涉及新型化合物（I），它们的前药以及药学上可接受的盐，以及包含这些化合物的药物组合物，在治疗某些代谢性疾病和通过抑制麦芽酰辅酶A脱羧酶（麦芽酰辅酶CoA脱羧酶，MCD）酶调节的疾病方面有用。特别是，本发明涉及化合物和组合物以及通过抑制麦芽酰辅酶A脱羧酶预防、管理和治疗心血管疾病、糖尿病、酸中毒、癌症和肥胖症的方法。